share_log

Allarity Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Graff Jeremy R.

Allarity Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Graff Jeremy R.

Allarity Therapeutics | 3:首次持股声明-高管 Graff Jeremy R.
美股SEC公告 ·  10/02 05:35

Moomoo AI 已提取核心信息

Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The document, dated 09/30/2024, indicates that Graff does not beneficially own any securities in the company. The filing was made in accordance with Section 16(a) of the Securities Exchange Act of 1934 and is a standard procedure for individuals in Graff's position, providing transparency about the holdings of company insiders. The form was filed by Graff as a single reporting person and was signed on 10/01/2024.
Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The document, dated 09/30/2024, indicates that Graff does not beneficially own any securities in the company. The filing was made in accordance with Section 16(a) of the Securities Exchange Act of 1934 and is a standard procedure for individuals in Graff's position, providing transparency about the holdings of company insiders. The form was filed by Graff as a single reporting person and was signed on 10/01/2024.
Allarity Therapeutics, Inc.的总裁兼首席发展官Jeremy R. Graff已根据SEC的Form 3要求提交了一份有关证券的有利所有权的初始声明。这份日期为2024年09/30的文件显示,Graff并不拥有公司的任何证券。该申报是根据1934年证券交易法案第16(a)条规定进行的,对于像Graff这样的个人是一种标准程序,可以透明地了解公司内部人士的持股情况。这份表格由Graff作为单一报告人提交,并在2024年10/01签署。
Allarity Therapeutics, Inc.的总裁兼首席发展官Jeremy R. Graff已根据SEC的Form 3要求提交了一份有关证券的有利所有权的初始声明。这份日期为2024年09/30的文件显示,Graff并不拥有公司的任何证券。该申报是根据1934年证券交易法案第16(a)条规定进行的,对于像Graff这样的个人是一种标准程序,可以透明地了解公司内部人士的持股情况。这份表格由Graff作为单一报告人提交,并在2024年10/01签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息